Condensed Consolidated Balance Sheets - USD ($) $ in Thousands	Mar. 31, 2019	Dec. 31, 2018
Current Assets
Cash and cash equivalents	$ 24,694	$ 28,918
Prepaid expenses and other current assets	860	593
Total Current Assets	25,554	29,511
Property and equipment, net	545	607
Right of use asset	510	0
Deposits and other assets	23	23
Total Assets	26,632	30,141
Current Liabilities:
Accounts payable	766	1,034
Accrued expenses	1,630	919
Warrant liabilities	0	0
Accrued employee benefits	341	1,332
Deferred rent	0	99
Lease liability	225	0
Total Current Liabilities	2,962	3,384
Long term deferred rent	0	302
Lease liability - Long term	662	0
Total Liabilities	3,624	3,686
Commitments and Contingencies
Series A convertible preferred stock, $0.001 par value; 10,000,000 shares authorized; 120,000 issued and outstanding	12,357	12,296
Stockholders' Equity:
Common stock, $0.001 par value; 250,000,000 shares authorized, 16,385,280, issued and 16,382,952 outstanding and 15,484,411, issued and 15,482,083 outstanding	16	15
Additional paid-in capital	231,817	230,754
Accumulated deficit	(223,432)	(219,461)
Total Synthetic Biologics, Inc. and Subsidiaries Equity	13,523	17,068
Non-controlling interest	(2,872)	(2,909)
Total Stockholders' Equity	10,651	14,159
Total Liabilities and Stockholders' Equity	26,632	30,141
Series B Preferred Stock [Member]
Stockholders' Equity:
Series B Convertible preferred stock, $1,000 par value; 10,000,000 shares authorized, 8,125 issued and outstanding	5,122	5,760
Total Stockholders' Equity	$ 5,122	$ 5,760